- [Resource Hub](/)
- [Resource](/?resource-type=poster#library)
- Non-invasive profiling of advanced prostate cancer via multi-parametric liquid biopsy and radiomics

# Non-invasive profiling of advanced prostate cancer via multi-parametric liquid biopsy and radiomics

Tissue biopsy is hard to repeat often enough to track treatment response in advanced prostate cancer; this AACR 2020 pilot study from the USC Norris Comprehensive Cancer Center profiled single circulating tumor cells, matched plasma cell-free DNA and CT-scan radiomics together in 23 patients with metastatic castrate-resistant disease.

Presented by USC Norris Comprehensive Cancer Center.

Read or download to see:

- Two CTC platforms were run side by side, and their counts tracked each other. Of 19 patients enumerated on both, CellSearch detected CTCs in 12 (63%; median 3 per 7.5 mL) and RareCyte in 14 (74%; median 1 per 7.5 mL); plotted against each other, the two counts gave R² = 0.88.

- Single CTCs and cell-free DNA each carried alterations the other did not. Across the cohort, 48 somatic alterations were identified in CTCs against 18 in cfDNA, spanning AR, TP53, CCND3, FGFR1, ALK and ROS1; of the 14 patients whose single CTCs were recovered, 12 (86%) had detectable somatic mutations in single-cell DNA versus 7 (50%) in matched cfDNA, and where both were sequenced most mutations were distinct rather than shared.

- CT-scan texture tracked CTC burden, reported by the authors as the first such association in metastatic prostate cancer. Radiomic entropy extracted from GLCM maps of bone metastatic lesions was associated with CellSearch CTC counts at an AUC of 0.74, using the FDA-cleared prognostic threshold for that platform of fewer than 5 versus 5 or more CTCs per 7.5 mL.

[Download poster](https://cdn.sanity.io/files/s3p6uqps/production/0703a5f56b5f99caf544a03bb704d9bf27d6e3ac.pdf)

Your browser doesn’t support embedded PDFs.
[Download the poster](https://cdn.sanity.io/files/s3p6uqps/production/0703a5f56b5f99caf544a03bb704d9bf27d6e3ac.pdf) to view it.

[Back to all resources](/#library)
## Related resources
[Publication](https://doi.org/10.1200/JCO.2026.44.16_suppl.5041) CyteFinder Journal of Clinical Oncology 2026
### Clinical validation of circulating tumor cell synaptophysin and androgen receptor expression in metastatic prostate cancer phenotypes.
[View Publication](https://doi.org/10.1200/JCO.2026.44.16_suppl.5041) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/691cd6e9b37a23fdd7d358244e8fcbac9fc2738b.pdf) 2026
### Clinical Validation of Circulating Tumor Cell Synaptophysin and Androgen Receptor Expression in Metastatic Prostate Cancer Phenotypes
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/691cd6e9b37a23fdd7d358244e8fcbac9fc2738b.pdf) [Video](https://www.youtube.com/watch?v=_oGC1KRVN2U) CyteFinder 2026
### Dr. Pashtoon Kasi on the impact of circulating tumor cells on clinical research
[Watch Video](https://www.youtube.com/watch?v=_oGC1KRVN2U) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12881594/) CyteFinder Nature Communications 2026
### Extracellular matrix mediates circulating tumor cell clustering in triple-negative breast cancer metastasis
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12881594/) [Publication](https://doi.org/10.1016/j.ejso.2025.111357) CyteFinder European Journal of Surgical Oncology 2026
### Circulating tumor cells predict relapse in head and neck mucosal squamous cell carcinoma
[View Publication](https://doi.org/10.1016/j.ejso.2025.111357) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805936/) CyteFinder Cancer Research Communications 2026
### Surface Marker Identification to Capture Live Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805936/) [Publication](https://doi.org/10.3390/cancers17162717) CyteFinder Cancers 2025
### Comprehensive Longitudinal Linear Mixed Modelling of CTCs Illuminates the Role of Trop2, EpCAM, and CD45 in CTC Clustering and Metastasis
[View Publication](https://doi.org/10.3390/cancers17162717) [Publication](https://doi.org/10.1080/07366205.2025.2534299) CyteFinder BioTechniques 2025
### A novel device for buffy coat collection
[View Publication](https://doi.org/10.1080/07366205.2025.2534299) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/246a94d07c9a47c844784f113f57f4415bf84a5c.pdf) CyteFinder 2025
### Development of a CTC Based Assay to Characterize MAOA Expression in Metastatic Prostate Cancer
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/246a94d07c9a47c844784f113f57f4415bf84a5c.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/43fb6d4a8510166e936d250b3bf172e2f669bfa3.pdf) CyteFinder 2025
### Quantitative analysis of HER2, HER3, and γH2AX expression on circulating tumor cells for pharmacodynamic measurement in clinical trials
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/43fb6d4a8510166e936d250b3bf172e2f669bfa3.pdf) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC11985722/) CyteFinder Cellular and Molecular Life Sciences 2025
### Portal venous circulating tumor cells as a biomarker for relapse prediction in resected pancreatic cancer
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC11985722/) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12092302/) CyteFinder Nature Medicine 2025
### Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12092302/)